Nektar Therapeutics Completes Public Offering of $115 Million
Nektar Therapeutics (NASDAQ: NKTR), a biotechnology company dedicated to advancing innovative therapies in immunotherapy, has successfully closed its underwritten public offering, raising a substantial $115 million. This funding arises from the sale of 4,893,618 shares of common stock, which included 638,298 shares sold as a result of the underwriters fully exercising their option to purchase additional shares at a public offering price of $23.50 per share.
Allocation of Proceeds for Future Growth
The funds generated from this offering will enable Nektar to focus on various corporate purposes, particularly in enhancing their research and development. This includes essential costs associated with clinical development and manufacturing needed to propel their promising drug candidates towards market readiness.
Key Players Behind the Offering
Nektar Therapeutics partnered with several financial institutions to facilitate this successful offering. The joint bookrunning managers were Jefferies and Piper Sandler, while BTIG, LLC served as a bookrunner. H.C. Wainwright & Co. took the lead manager role, ensuring a well-structured process throughout the offering.
Company Commitment to Transparency
The shares of common stock were issued under a previously filed shelf registration statement with the appropriate regulatory bodies. Nektar has committed to transparency by providing detailed documentation related to the terms of this offering and ensures all information is accessible to interested investors.
About Nektar Therapeutics
Nektar Therapeutics is renowned for its innovative approaches to treating autoimmune and chronic inflammatory diseases. Its leading product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a pioneering regulatory T cell stimulator currently undergoing evaluation in two Phase 2b clinical trials targeting atopic dermatitis and alopecia areata. In addition, Nektar's portfolio features several other promising candidates, such as NKTR-0165 and NKTR-0166, intended to stimulate the immune response against cancer and enhance treatment options in immunotherapy.
Continued Commitment to Development
As Nektar Therapeutics moves forward, it aims to leverage this funding to boost its pipeline and further enhance its clinical trials. The company remains dedicated to pushing the boundaries of immunotherapy and exploring the potential of its drug candidates to treat patients suffering from various conditions.
Frequently Asked Questions
What is the total amount raised by Nektar Therapeutics?
Nektar Therapeutics raised a total of $115 million through its public offering.
What will the raised funds be used for?
The funds will support research and development, clinical development, and manufacturing costs for Nektar Therapeutics' drug candidates.
Who managed the public offering?
The offering was managed by Jefferies, Piper Sandler, and BTIG, LLC, among others.
What is rezpegaldesleukin?
Rezpegaldesleukin (REZPEG or NKTR-358) is Nektar's lead product candidate, designed to stimulate regulatory T cells for treating autoimmune diseases.
How does Nektar Therapeutics ensure transparency in its offerings?
Nektar Therapeutics provides necessary documentation relating to its offerings through filings with the appropriate regulatory bodies.
